Introduction
============

Plasmatic viral load strongly predicts T CD4^+^ cell count decline, AIDS progression and death. Anyway, disease prognosis in HIV infected subjects is more rigorously defined by the combination of plasmatic viral load quantification and T CD4^+^ cell count.[@b1-dti-5-2011-033] It is internationally noted that the main predictive factors for failure of antiretroviral therapy are T CD4^+^ cells low count and elevated viral load before commencing treatment.[@b2-dti-5-2011-033] The efficacy of the Highly Active Antiretroviral Therapy (HAART) and the pattern of therapy management could be evaluated based on plasmatic RNA viral load assessement. In HIV/AIDS treatment the response is considered successful when the HIV RNA levels remain undetectable by certified commercial assays, notwithstanding in a variable proportion of HAART submitted patients, the viral replication and evolution goes on which could eventually contribute to the development of antiretroviral drug resistance and therapeutic failure.[@b3-dti-5-2011-033]

Unsuccessful antiretroviral therapy could occur due to virologic and immunologic failure and clinical manifestations that can appear during the course of HIV infection. The identification of therapeutic failure is based on patient follow-up during treatment, taking into account the initial level of T CD4^+^, plasmatic HIV RNA load and the patient clinical evolution. Also, many factors could be related to therapeutic failure such as low treatment adhesion, insufficient drug dosage, mal-absorption, HIV antiretroviral resistance and drug interactions that could reduce the efficacy and HIV resistance to antiretroviral medications. Patients that failed to respond to antiretroviral therapy confirmed by the genotype resistant assay will be guided to choose new drugs. This choice is based on the knowledge of previous treatments and yet the reason to remove a drug from the antiretroviral regimen is mainly justified by the in vitro antiretroviral resistance profile. The antiretroviral therapeutic suspension as an alternative therapy is based on the reemergence of the initial virus population before treatment initiation, which would be susceptible to the antiretroviral drugs earlier prescribed, so this proposal is presently under evaluation. The essential objective of treatment in patients presenting therapeutic failure is to maintain T CD4^+^ acceptable cell population density, whilst new therapeutic options are awaited, contrary to the priority aim to reach and keep up an undetectable viral load.[@b4-dti-5-2011-033] According to Moore et al,[@b5-dti-5-2011-033] virological failure is characterized by viral load higher than 400 copies/mL after 48 weeks of initial treatment or among subjects that had complete viral suppression, but later on the viral load will recrudesce. The viral failure precedes the immunologic failure which is defined by a decline of more than 25.0% in the subsequent count of T CD4^+^ lymphocytes or regresion to the initial T CD4^+^ cell count before treatment. These conditions are mainly suggestive of immunologic failure but laboratory analysis confirmation is mandatory.[@b6-dti-5-2011-033] Cozzi-Lepri et al[@b7-dti-5-2011-033] concluded that patients remaining in HAART failure presented viral load slowly progressing during the next 12 months, differently to T CD4^+^ cell count which remained stable.

The impact of HAART on T CD4^+^ cell count and viral load of HIV infected patients has been demonstrated to improve the patient's immunological status and it also diminished the viral load, interrupting the AIDS progression.[@b8-dti-5-2011-033] However there are crucial limitations of HAART regimen, as it does not eradicate viral infection despite long and permanent antiretroviral therapy. Consequently, a significant number of these patients on HAART therapy develop viral resistance to the drugs besides diverse side effects including metabolic disorders. Therefore new approaches are necessary to control and/or eradicate HIV infection.[@b9-dti-5-2011-033],[@b10-dti-5-2011-033]

This research work aimed to analyze T CD4^+^ cell density and viral load response in HIV infected patients undergoing different therapeutic regimens which failed virologically, and also the associated factors to it during 2002--2008 in Brasilia, Federal District, Brazil.

Material and Methods
====================

Patients
--------

A cohort study was conducted in the Health Center Number 01 attached to the Secretary of Health, Federal District (SES/DF) (Centro de Saúde Número 01, Secretaria de Saúde do Distrito Federal) which included 139 HIV-1 infected patients. The patients had clinical and laboratory diagnosis as defined by the 1993 AIDS clinical course criteria and by the US Center for Disease Control (CDC)[@b11-dti-5-2011-033] and also by the recommendations of the Brazilian Consensus of Antiretroviral Therapy in Infected Adults and Adolescents by the Ministry of Health, Secretary of Health Surveillance, Brazilian National Program of Sexually Transmitted Diseases and AIDS.[@b12-dti-5-2011-033] Patients selected for the study were identified in the records of Logistic System of the Ministry of Health, SICLOM[@b13-dti-5-2011-033] utilized by the Hospital Dia, SES/DF.

The plasmatic HIV RNA load was quantified by the BDNA system 340 presenting sensitivity of less than 50 copies/mL. The T CD4^+^ helper lymphocytes' count was carried out by automatized flow cytometry utilizing the FacScalibur Count^®^ System. The sampling utilized for patient selection was by convenience whose inclusion criteria were: (a) age higher than 18 years old and of both sexes; (b) HIV infection diagnosis defined by the Brazillian Ministry of Health standardized patterns; (c) detectable viral load previous to HAART beginning \>400 copies/mL; (d) T CD4^+^ cell count \<500 cells/mm^3^ before HAART regimen initiation; (e) present laboratory analysis for viral load and T CD4^+^ count between 6 and 12 months in order to compare the former ones with those of baseline; (f) patients have had clinical and immunological follow up during 3 months intervals.

If undetectable viral load of 50 copies/mL was not sustained during 24 weeks of treatment or higher than 400 copies/mL after 48 weeks treatment, it was considered virological failure to the initial antiretroviral therapeutic regimen.[@b5-dti-5-2011-033] Immunological failure was considered by the declining of T CD4^+^ cell counting ≥ 25.0% of the absolute values[@b6-dti-5-2011-033] or by returning to the T CD4^+^ cell count initial values before antiretroviral therapy initiation.

The viral load previous to HAART regimen initiation and T CD4^+^ cell count were evaluated as possible predictors of viral failure leading us to establish the cut off values to viral load \> 100.000 copies/mL or ≤100.000 copies/mL as also T CD4^+^ \> 200 cells/mm^3^ or ≤200 cells/mm^3^.

The antiretroviral therapy regimen were: (a) double with two nucleoside reverse transcriptase inhibitor and non nucleoside reverse transcriptase inhibitor; (b) triple with two nucleoside reverse transcriptase inhibitor and one protease inhibitor and (c) three nucleoside reverse transcriptase inhibitor, according to CDC classification and the Brazilian Ministry of Health guidelines as previously described. In the population here studied, the chosen antiretroviral regimen was decided by the physician in charge without interference by the authors of this research work.

The criteria for the diagnosis of Hepatitis B and C virus infection followed the guidelines established by the Manual of Viral Hepatitis Consultancy, Secretary of Health Surveillance, Department of Epidemiological Surveillance, Brasília, Ministry of Health[@b14-dti-5-2011-033] and also for the tuberculosis diagnosis, the Technical Manual for Tuberculosis Control, Notebook of Basic Attention, Secretary of Health Politics, Department of Basic Attention, Brasília. Ministry of Health.[@b15-dti-5-2011-033]

The exclusion criteria for this research were: (a) be pregnant or minor under 18 years old; (b) be prescribed with medications which could metabolically interact with antiretroviral drugs, including phytotherapics; (c) have had last clinical appointment in a period longer than 6 months which was considered lost to follow-up.

The analysis of baseline characteristics (initial data previous to initiation of treatment referring to T CD4^+^ cell count and viral load) included frequency tables of categorical variables and their descriptive statistics (median, arithmetic mean and standard deviation) as also as continuous variables. In order to measure the dependent association between two categorial variables it was utilized the Chi-square test (*x*^2^) or when necessary the exact Fisher test. To compare before and after results the MacNemar test was applied. For the analysis of logistic regression and to predict the event of virological failure[@b16-dti-5-2011-033] (depedent variable), the WALD method was applied. The association measurement calculated from the logistic model is the adjusted odds ratio (OR). The statistical analysis was carried out utilizing SPSS 17.0. The statistical association was considered when *P* \< 0.05.

The patients' data were confidential and consentment to utilize information were obtained at the Health Center Number 01 direction according to the Federal District Secretary (SES/DF) of Health agreement. The research work protocol was approved by the Federal District Secretary of Health Researh Ethics Committee, Foundation of Teaching and Research in Health Sciences (FEPECS).

Results and Discussion
======================

Initially, 165 patients were eligible to participate in the study for starting the treatment in the period 2002--2008. However, only 139 patients met the inclusion criteria. Among them ([Table 1A](#t1A-dti-5-2011-033){ref-type="table"} and [B](#t1B-dti-5-2011-033){ref-type="table"}), males predominated (74.1%). Ages ranged from 20--65 years old (mean = 39.7 years, median = 40.0). There was a slight predominance of patients in the range of 41--65 years old (51.1%) compared to younger patients. As for race/ethnical background, there was a predominance of mestizos (54.6%). Regarding to the marital status, there was a predominance of single people (48.2%). High school education (25.9%) predominated over other categories. People living in Taguatinga (13.7%), a satellite city located in the surrounding areas of Brasília, represented the majority of the patients enrolled in this study. The place of birth showed that patients predominated from the Midwest (40.3%) and the Northeast of Brazil (34.5%). Hetrosexual relationships predominated (51.8%), followed by the homosexual relationships (23.7%).

The initial viral load ranged between 1.643 copies/mL to 500.000 copies/mL (mean = 180.721 copies/mL; arithmetic mean = 126.417 copies/mL) presenting more than half of the patients (55.4%) cell density higher than 100.000 copies/mL ([Table 2](#t2-dti-5-2011-033){ref-type="table"}). After antiretroviral therapy, the initial profile changed substantially more than 70% of the patients had viral load lower than 50 copies/mL. In reference to the initial T CD4^+^ cell count, 68.3% of the patients were in the range of 0--200 cells/mm^3^. After treatment a relevant change was observed in the patients profile concerning T CD4^+^ cell counts, remaining less than 37% of the cases in this stage. In the following cell density interval, there was an expressive increment in the number of cases, representing more than 43.0% of the patients ([Table 2](#t2-dti-5-2011-033){ref-type="table"}). Initially the most utilized antiretroviral regimen included two drugs, the nucleoside reverse transcriptase inhibitor and non nucleoside reverse transcriptase inhibitor in 71.2% of the cases and the remaining 28.1% included two nucleoside reverse transcriptase inhibitor and one protease inhibitor. During the course of the treatment, the presented regimen distribution slightly changed to 66.9% to the first drug combination and 32.4% to the second one, there remaining only one utilizing three nucleoside reverse transcriptase inhibitor ([Table 2](#t2-dti-5-2011-033){ref-type="table"}).

Virologic failure was 12.2% ([Table 3](#t3-dti-5-2011-033){ref-type="table"}), or antiretroviral treatment success was 88.8%, exceeding the results obtained by Johnson and Way of 80%.[@b17-dti-5-2011-033] Among the socioeconomic and demographic variables, just the birthplace and the fact that originating in the Midwest Region which includes the Federal District, was associated with the occurrence of virologic failure in the study. Cole et al[@b18-dti-5-2011-033] stated that HIV infection is sufficiently widespread, suggesting that it is a multidimensional epidemic, with demographic, residential, social, biological and behavioral significance. Perhaps this is a natural social structural marker as the study was conducted in the Midwest region compared to those migrating people from other regions to the Federal District. There was a trend toward a higher incidence of virologic failure being male, over 40 years old, mestizo, unmarried or separate and also heterossexual exposure category. However, there was not any statistical significance of such associations. It was found that only the birthplace presented statistical significance. Patients from the Midwestern had 2.7 times greater risk of virologic failure than those from other regions of Brazil, especially because the study was conducted in Brasilia, which is part of this region.

In this study, the initial viral load is not statistically associated and significant to the occurrence of virologic failure. However, there is the presence of a higher incidence of virologic failure among those who had viral load greater than 100.000 copies/mL after the introduction of HAART. The virologic target for patients on HAART is to achieve viral load plasma levels below 50 copies/mL when two or more potent drugs are used. These results highlight the importance of compliance with primary success and reinforces the need to work on the accession of such patients. Some authors[@b19-dti-5-2011-033] interpret and agree that those with viral load higher than the baseline level of 100.000 copies/mL had a slower pace to achieve viral suppression. However, a potent and well tolerated prophylactic regimen with HAART can improve CD4^+^ T cell count at the beginning, during and after treatment. Kantor et al[@b2-dti-5-2011-033] concluded that plasma viral load strongly predicts the rate of CD4^+^ lymphocyte count decrease, progression to AIDS and death. But the prognosis for people infected with HIV is more strictly defined by the combination of plasma viral load measurement and CD4^+^ lymphocytes' counts.

Some patients with viral load higher than 100.000 copies/mL remained in treatment failure after HAART regimen in contrast to T CD4^+^ lymphocyte counts decrease at a slower pace, leaving some in virologic failure, probably due to the emergence of HIV resistant strains. Cozzi-Lepri et al[@b7-dti-5-2011-033] advocate that patients who remained in HAART regimen failure, the viral load in the next twelve months was growing at a relatively slow pace, the CD4^+^ T cell count was stable and the time course of viral replication in patients with virological failure had not been fully elucidated. Asjo and Langeland[@b20-dti-5-2011-033] suggest that the lack of complete suppression of viral replication allows the continued development of HIV variants with different degrees of resistance. It results not only in treatment failure, but it also increases the risk of HIV primary resistance and dissemination.

Patients with initial CD4^+^ T cell count ≤ 200 cells/mm^3^ had a tendency to virologic failure, however, there was not any statistical significance. Tuberculosis coinfection was associated with virologic failure demonstrated with statistical significance, *P* = 0.019. Patients with a previous diagnosis of tuberculosis infection had 2.9 times great risk of virologic failure.

It is observed that the T CD4^+^ cell count baseline above 200 cells/mm^3^ was not statistically associated with virological failure, but the incidence of failure in this group was noticeably lower than in those with initial T CD4^+^ less than 200 cells/mm^3^. Studies conducted by Skowron et al[@b21-dti-5-2011-033] demonstrated that T CD4^+^ cell count is a better predictor of viral suppression. However, in order to achieve viral load suppression to undetectable levels, it is necessary to have an optimal response of T CD4^+^ cell count in patients under antiretroviral therapy. Piliero[@b22-dti-5-2011-033] comments that the maximum suppression of viral replication remains the primary goal of therapy after HAART regimen, therefore T CD4^+^ cell count and HIV plasma viral load values are the prognostic markers for treatment success after four, eight or twelve weeks post treatment, as the changes are predictive of favorable long-term success in six months or more.

According to Moreno et al[@b23-dti-5-2011-033] in multifailed patients, at least two active drugs can not be used, the therapeutic scheme should be kept in use until new drugs become available, assuming that there is an immunologic and clinical stability in order to avoid the use of a drug from a common chemical group which usually leads to a rapid viral resistance development, further limiting future treatment options. Geretti et al[@b24-dti-5-2011-033] stated that patients in first HAART line who maintained consistently undetectable plasma viral load for a year, had a low risk of virologic failure.

In this study, the tuberculosis comorbidity had significant influence on the occurrence of virologic failure. Special attention should be given to early tuberculosis diagnosis during the early HAART regimen prescription. Studies reported by Bekker et al[@b25-dti-5-2011-033] and von Reyn et al[@b26-dti-5-2011-033] showed that the mycobacterial disease was a major contributor to HIV mortality. In addition, the infection increases the risk of latent tuberculosis reactivation, a new infection progression or re-infection to active disease, increasing the risk of the emergence of HIV resistant strains to the usual antiretroviral therapy. Tuberculosis also accelerates the course of HIV induced disease by activating viral replication and accentuating the decline of T CD4^+^ cells.

In the logistic regresion analysis the best model to explain the event of virological failure is the one that includes variables such as origin and infection by *M. tuberculosis*, yielding OR values of 3.2 and 3.8 respectively.

Conclusion
==========

Despite the enormous progress as a result of the impact of HAART-related morbidity and mortality in patients with HIV/AIDS continue and will continue to fail in the face of the therapeutic classes of HAART currently available. The presented results reinforce the importance of monitoring the biological markers T CD4^+^ cells and viral load in patients living with and without AIDS, both to ensure that viral replication is under control and to reassure the maintenance of immune reconstitution compatible with life, and to predict the risk of developing resistance and therapeutic failures in the course of the treatment of HIV-infected people.

It should be noted that the sample size limited the analysis of this study, as the retrospective information taken from the medical records, excluded some data from the laboratory and the clinical follow up. The sample obtained in this way may have had a limited ability to highlight the predictive differences of risk for both T CD4^+^ cell count and viral load in naive patients. It is possible that working with a larger cohort of patients and longer follow-up of these predictors probably would show more consistent evidence that is statistically supported. Initial treatment with any NNRTI-based regimen or an IP, but not both, is a good strategy for managing the long-term antiretroviral treatment in naive HIV patients. Moreover, the recent availability of new antiretroviral agents for the treatment of HIV has increased treatment options and improved durability, tolerability and efficacy in the long-term HAART regimen.

Other limitations that should be highlighted refer to the possibility of verifying the association of HBV and HCV coinfections which do not have evolutionary studies of these HIV comorbidities. It is possible that if we had a homogeneous group of patients already in advanced stages of these pathologies, the risk of virologic failure would be high. The sociodemographic data were collected from medical records and not through interviews, this fact may also have skewed the results of the analysis of association between these variables and treatment failure. However, this service data and variables accounted are limitations imposed by real situations in nosocomial institutions in the Federal District in Brazil.

It is of great relevance to the findings in this study considering the limitations and difficulties of conducting studies in routine service, as it can be concluded that even in the non-ideal conditions of a clinical trial, patients treated in this unit had virological success of 12.2% up to one year of treatment, a fact that can predict the durability of the first scheme which is better than expected in many other international centers.[@b17-dti-5-2011-033] Also tuberculosis infection should be traced as a priority as early as possible. As the low values of T CD4^+^ cell counts and high viral load pre-treatment should be considered to implement the prescribed antiretroviral therapy, especially when new classes are available and have superior performance, as much viral suppression and immune reconstitution could be achieved.
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###### 

Distribution of socioeconomic and demographic profiles of patients attended at Health Center No. 1 (Hospital Dia) during 2002--2008.

  Variable                   Category                          N     \%
  -------------------------- --------------------------------- ----- -------
  Sex                        Male                              103   74.1
                             Female                            36    25.9
  Age                        20--40                            68    48.9
                             41--65                            71    51.1
  Race/ethnical background   White                             60    43.2
                             Mestizo                           76    54.6
                             Black                             3     2.2
  Marital status             Single                            67    48.2
                             Married                           41    29.5
                             Stable                            18    12.9
                             Separate                          10    7.2
                             Widow                             3     2.2
  Education                  Incomplete elementary schooling   28    20.1
                             Complete elementary schooling     24    17.3
                             Middle incomplete schooling       19    7.2
                             Middle complete schooling         36    25.9
                             Incomplete higher schooling       4     2.9
                             Complete college schooling        27    19.4
                             Illiterate                        9     6.5
                             Not informed                      1     0.7
  Total                                                        139   100.0

**Source:** SICLOM (MS-Brazil).

###### 

Distribution of socioeconomic and demographic profile of patients attended in the Health Center No. 1 (Hospita Dia) during 2002--2008.

  Variable            Category            N     \%
  ------------------- ------------------- ----- ------
  Residence           Pilot Plan          29    20.9
                      Guara               16    11.5
                      Ceilandia           17    12.2
                      Taguatinga          19    13.7
                      Bandeirante         9     6.5
                      Gama                14    10.0
                      Sobradinho          3     2.2
                      Planaltina          4     2.9
                      San Sebastian       7     5.0
                      Paranoa             2     1.4
                      Around Brasília     19    13.7
  Birthplace          North               4     2.9
                      Northeast           48    34.5
                      South               4     2.9
                      Southeast           25    18.0
                      Midwest             56    40.3
                      African continent   2     1.4
  Exposure category   Accident at work    1     0.7
                      Bisexual            23    16.7
                      Heterosexual        72    51.8
                      Homosexual          33    23.7
                      Blood transfusion   1     0.7
                      UDI                 9     6.6
  Total                                   139   100

**Source:** SICLOM (MS-Brazil).

**Abbreviation:** UDI, User injecting drug.

###### 

Viral load and T CD4^+^ cell counts distribution in 139 patients submitted to antiretroviral therapy in the Health Center No. 1 (Hospital Dia) during 2002--2008.

  Variable                                         Category                        N     \%
  ------------------------------------------------ ------------------------------- ----- ------
  Initial viral load (treatment-naive)             \<50 copies/mL                  0     0
                                                   50.1--400 copies/mL             0     0
                                                   400.1--10,000 copies/mL         5     3.6
                                                   10,000.1--100,000 copies/mL     57    41.0
                                                   100,0000.1--500,000 copies/mL   77    55.4
  Viral load after HAART                           \<50 copies/mL                  99    71.2
                                                   50.1--400 copies/mL             20    14.4
                                                   400.1--10,000 copies/mL         10    7.2
                                                   10,000.1--100,000 copies/mL     8     5.8
                                                   100,000--500,000 copies/mL      2     1.4
  Initial T CD4^+^ cell counts (treatment-naive)   0--200 cells/mm^3^              96    68.4
                                                   200.1--350 cells/mm^3^          37    26.6
                                                   351--500 cells/                 7     5.0
                                                   above de 500 cells/mm^3^        0     0
  T CD4^+^ cell counts after HAART                 0--200 cells/mm^3^              51    36.7
                                                   200.1--350 cells/mm^3^          60    43.2
                                                   351--500 cells/mm^3^            21    15.1
                                                   above de 500 cells/mm^3^        7     5.0
  HAART                                            2 ITRN + 1 ITRNN                99    71.2
                                                   2 ITRN + 1 IP                   39    28.1
                                                   3 ITRN                          1     0.7
                                                                                   139   100

**Abbreviations:** HAART, highly active antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor.

###### 

Distribution of variables, viral load, T CD4^+^ cell counts, HAART and comorbidity in relation to the significance of virologic failure in patients treated at the Health Centre No. 1 (Hospital Dia) during 2002--2008.

  Variable            Category                             VF    N    CI%    RR     CI95%        *P*
  ------------------- ------------------------------------ ----- ---- ------ ------ ------------ -------
  Sex                 Male                                 103   14   13.6   1.63   0.49--5.35   0.407
                      Female                               36    3    8.3                        
  Age                 41--65                               60    10   16.7   1.88   0.76--4.75   0.164
                      20--40                               79    7    8.9                        
  Race                Mestizo                              79    10   12.7   1.08   0.43--2.68   0.860
                      White                                60    7    11.7                       
  Marital status      Single/separate                      80    11   13.8   1.35   0.53--3.44   0.524
                      Married/stable union                 59    6    10.2                       
  Education           NF incomplete/illiterate             38    6    15.8   1.45   0.57--3.64   0.432
                      Other school levels                  101   11   10.9                       
  Residence           Brasilia suroundings                 19    3    15.8   1.35   0.42--4.27   0.610
                      Pilot plan/satellite city            120   14   11.7                       
  Birthplace          Midwest                              56    11   19.6   2.71   1.06--6.92   0.028
                      North, northeast, south, southeast   83    6    7.2                        
  Exposury category   Heterosexual                         83    11   13.3   1.23   0.48--3.15   0.654
                      Homosexual                           56    6    10.7                       

**Abbreviations:** N, patients number; VF, virological failure; CI, incidence coefficient; RR, relative risk; IC95**%,** interval confidence; *P*, significance: NF, Uninformed.

###### 

Distribution of association of viral load, T CD4^+^ cell count, HAART and comorbidities in terms of the significance of virologic failure in patients treated at the Health Centre No. 1 during the years 2002 to 2008.

  Variable                    Category           N     VF   IC%    RR     IC95%        *P*
  --------------------------- ------------------ ----- ---- ------ ------ ------------ -------
  Viral load after HAART      \>100.000          77    10   13.0   1.15   0.46--2.84   0.762
                              ≤100.000           62    7    11.3                       
  T CD4^+^ cell after HAART   \>200              95    8    10.5   0.66   0.27--1.63   0.368
                              ≤200               44    9    15.9                       
  HAART                       2 ITRN + 1 ITRNN   100   12   12.0   0.93   0.35--2.48   0.804
                              2 ITRNN + 1 IP     39    5    12.8                       
  HCV (HCV-anti)              Positive           10    1    10.0   0.80   0.11--3.47   0.823
                              Negative           129   16   12.4                       
  HBV (HBsAg)                 Positive           31    3    9.7    0.74   0.22--2.43   0.623
                              Negative           108   14   13.9                       
  TB (BAAR)                   Positive           22    6    27.3   2.90   1.19--7.02   0.019
                              Negative           117   11   10.3                       
  Total                                          139   17                              

**Abbreviations:** HAART, antiretroviral therapy; T CD4^+^, lymphocyte count; N, number of patients; VF, virologic failure values; CI, incidence rate; RR, relative risk; IC95%, confidence interval; *P*, significance; HCV, antibody to the hepatitis "C" virus; HBV, antibody against hepatitis "B" virus antigens; TB, tuberculosis; BAAR, Alcohol acid resistant bacilli.

###### 

Logistic regresion in patients attended in the Health Center No. 1 (Hospital Dia) from 2002 to 2008.

  Step      Variable                 β         Wald test   *P*-value   Odds ratio   IC95%
  --------- ------------------------ --------- ----------- ----------- ------------ ---------------
  Step 1    Gender                   1.142     1.718       0.182       3.132        0.586--16.746
            Age                      0.894     1.906       0.167       2.444        0.687--8.692
            Skin colour              0.059     0.007       0.932       1.061        0.274--4.107
            Marital status           0.512     0.588       0.443       1.668        0.451--6.170
            Education                0.745     1.129       0.288       2.106        0.533--8.319
            Zone                     0.149     0.034       0.854       1.160        0.237--5.683
            Birthplace               1.240     3.656       0.056       3.454        0.969--12.310
            Expsosure category       0.580     0.475       0.491       1.786        0.343--9.301
            Viral load after HAART   21.291    0.000       1.000       0.000        0.000--0.000
            T CD4^+^ after HAART     0.451     0.417       0.518       1.569        0.400--6.156
            HAART                    −0.112    0.023       0.880       0.894        0.207--3.851
            HBV (HBsAg)              −0,539    0,210       0,647       0,583        0,058--5,859
            HCV (anti HCV)           −0.356    0.191       0.662       0.701        0.142--3.450
            TB (B.A.A.R.)            1.107     2.536       0.111       3.025        0.775--11.810
            Constant                 −48.150   0.000       1.000       0.000        0.000--0.000
  Step 14   Age                      0.812     2.125       0.145       2.252        0.756--6.707
            Birthplace               1.308     5.247       0.022       3.698        1.208--11.322
            TB (B.A.A.R.)            1.311     4.786       0.029       3.710        1.146--12.008
            Constant                 −3.508    4.353       0.037       0.030        0.000--0.000
  Paso 15   Birthplace               1.188     4.584       0.032       3.280        1.106--9.731
            TB (B.A.A.R.)            1.340     5.098       0.024       3.820        1.194--12.229
            Constant                 −2.173    2.567       0.109       0.114        0.000--0.000

**Abbreviations**: β, maximum likehood values; HAART, antiretroviral therapy; CD4^+^, lymphocyte count; IC95%, confidence interval; HCV, Hepatitis C Virus; anti HCV, antibody to the hepatitis "C" virus; HBV, Hepatitis B Virus; HBsAg, Hepatitis B Virus surface antigen; TB, tuberculosis; B.A.A.R, Alcohol acid resistant bacilli.
